Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

Study identifier:ROF-ALZ_102

ClinicalTrials.gov identifier:NCT02051335

EudraCT identifier:2012-002089-11

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults

Medical condition

Memory impairment

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Roflumilast, Roflumilast placebo, Donepezil, Donepezil placebo, Scopolamine

Sex

Male

Actual Enrollment

27

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jan 2014
Primary Completion Date: 01 May 2014
Study Completion Date: 01 May 2014

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria